[HTML][HTML] Epigenetic alterations and advancement of lymphoma treatment
S Zhuang, Z Yang, Z Cui, Y Zhang, F Che - Annals of Hematology, 2024 - Springer
Lymphomas, complex and heterogeneous malignant tumors, originate from the
lymphopoietic system. These tumors are notorious for their high recurrence rates and …
lymphopoietic system. These tumors are notorious for their high recurrence rates and …
Rational targets of therapy in extranodal NK/T-cell lymphoma
A Major, P Porcu, BM Haverkos - Cancers, 2023 - mdpi.com
Simple Summary Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive blood cancer
with poor survival rates, particularly for patients with advanced-stage and relapsed disease …
with poor survival rates, particularly for patients with advanced-stage and relapsed disease …
[PDF][PDF] 进展期及复发难治性结外NK/T 细胞淋巴瘤的治疗进展
梁凤桑 - 中国医学创新, 2023 - zgyxcx.com
结外NK/T 细胞淋巴瘤(ENKTL) 是一种进展迅速, 恶性程度高, 预后差的结外淋巴瘤类型,
临床上治疗ENKTL 的方法有很多, 但目前为止尚无标准的治疗方案. 近年来, 早期ENKTL …
临床上治疗ENKTL 的方法有很多, 但目前为止尚无标准的治疗方案. 近年来, 早期ENKTL …
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports
VM Rivera-Francia, VE Failoc-Rojas… - Leukemia & …, 2024 - Taylor & Francis
Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin's lymphoma with
limited treatment options for patients who experience disease progression or recurrence …
limited treatment options for patients who experience disease progression or recurrence …
Intensive therapy can improve long‐term survival in newly diagnosed, advanced‐stage extranodal NK/T‐cell lymphoma: A multi‐institutional, real‐world study
YC Wei, F Qi, BM Zheng, CG Zhang… - … Journal of Cancer, 2023 - Wiley Online Library
The study investigated the treatment and prognosis of advanced‐stage extranodal natural
killer/T‐cell lymphoma (ENKTL). With a median follow‐up of 75.03 months, the median …
killer/T‐cell lymphoma (ENKTL). With a median follow‐up of 75.03 months, the median …
[HTML][HTML] Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential …
F Qi, W Zhou, Y Xie, Y Sun, M Wu, Y Chai… - Aging (Albany …, 2022 - ncbi.nlm.nih.gov
Objective: We aimed to assess the association between induction chemotherapy (CT)
response and survivals and to explore an induction CT response-adapted treatment strategy …
response and survivals and to explore an induction CT response-adapted treatment strategy …
Sintilimab and chidamide for refractory transformed diffuse large B cell lymphoma: A case report and a literature review
C Chen, W Zhang, D Zhou, Y Zhang - Frontiers in Oncology, 2021 - frontiersin.org
Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL)
have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been …
have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been …
[PDF][PDF] 复发难治性鼻型结外NK/T 细胞淋巴瘤的治疗研究进展
张民安, 王瑶, 施文瑜, 张亚平 - 临床血液学杂志, 2023 - lcxy.whuhzzs.com
鼻型结外NK/T 细胞淋巴瘤(ENKTL) 是侵袭性非霍奇金淋巴瘤的一种, 临床预后较差.
尽管目前临床上以左旋门冬酰胺酶为核心的多种化疗方案的应用使患者预后得到明显改善 …
尽管目前临床上以左旋门冬酰胺酶为核心的多种化疗方案的应用使患者预后得到明显改善 …
[HTML][HTML] Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
J Wang, YS Gao, K Xu, XD Li - World Journal of Clinical Cases, 2022 - ncbi.nlm.nih.gov
BACKGROUND The prognosis of refractory extranodal natural killer/T-cell lymphoma
(ENKTL) is poor. Recent data have indicated that immune checkpoint blockade with a …
(ENKTL) is poor. Recent data have indicated that immune checkpoint blockade with a …
Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review
C Chen, Z Liu, J Liu, W Zhang, D Zhou… - Frontiers in …, 2022 - frontiersin.org
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma with
a poor prognosis and survival rate. Existing therapies for relapsed/refractory (R/R) SS have …
a poor prognosis and survival rate. Existing therapies for relapsed/refractory (R/R) SS have …